Celyad SA Company Profile
Celyad SA, a clinical-stage biopharmaceutical company, focuses on engineered cell therapy treatments. It develops therapeutic therapies for the treatment of unmet medical needs in cardiology and oncology. The company offers C-Cure, an autologous cell therapy for the treatment of heart failure. It also provides NKR-2, an autologous chimeric antigen receptor (CAR), a lab engineered receptor for the treatment of cancer. In addition, the companys pre-clinical stage product candidates include NKp30, an activated receptor of NK cells; B7H6 therapies, which kills cancer cells; and CAR T-cell, an allogeneic T-cell platform. Further, it offers C-CATHez, a cell injection catheter; heart access sheaths; mitral valve neo-chordaes; and closure devices. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.